Thermo Fisher Scientific Inc (NYSE:TMO) – Leerink Swann decreased their Q4 2017 earnings estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Thursday, Zacks Investment Research reports. Leerink Swann analyst P. Souda now forecasts that the medical research company will post earnings of $2.65 per share for the quarter, down from their prior forecast of $2.68. Leerink Swann currently has a “Buy” rating on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q1 2018 earnings at $2.37 EPS, Q4 2018 earnings at $2.86 EPS, FY2018 earnings at $10.44 EPS and Q1 2019 earnings at $2.65 EPS.
Several other brokerages also recently weighed in on TMO. Deutsche Bank AG set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Cowen and Company reiterated an “outperform” rating and issued a $220.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Barclays PLC reissued an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $205.71.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/11/13/q4-2017-eps-estimates-for-thermo-fisher-scientific-inc-tmo-reduced-by-analyst.html.
Shares of Thermo Fisher Scientific (NYSE TMO) traded down $5.71 during trading on Friday, reaching $186.18. 3,009,200 shares of the company were exchanged, compared to its average volume of 1,574,792. Thermo Fisher Scientific has a one year low of $139.07 and a one year high of $201.20. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $74,657.24, a P/E ratio of 20.46, a P/E/G ratio of 1.71 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period last year, the business earned $2.03 earnings per share.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank lifted its stake in Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after buying an additional 16,308 shares during the last quarter. BB&T Securities LLC raised its stake in shares of Thermo Fisher Scientific by 4.4% during the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock valued at $13,798,000 after purchasing an additional 3,819 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 2.1% during the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares in the last quarter. Mitchell Capital Management Co. raised its stake in shares of Thermo Fisher Scientific by 40.3% during the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after purchasing an additional 12,910 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after purchasing an additional 5,213 shares in the last quarter. Hedge funds and other institutional investors own 83.66% of the company’s stock.
In other Thermo Fisher Scientific news, Director C Martin Harris sold 360 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares of the company’s stock, valued at $961,312.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the sale, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,738 shares of company stock valued at $4,021,512. Corporate insiders own 0.49% of the company’s stock.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.